{"id":811861,"date":"2025-02-12T02:03:09","date_gmt":"2025-02-12T07:03:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\/"},"modified":"2025-02-12T02:03:09","modified_gmt":"2025-02-12T07:03:09","slug":"maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\/","title":{"rendered":"MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs"},"content":{"rendered":"

\nTG Therapeutics to use MaxCyte\u2019s Flow Electroporation\u00ae technology and ExPERT\u2122 platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for the treatment of autoimmune diseases
\n<\/h2>\n
\n

ROCKVILLE, Md., Feb. 12, 2025 (GLOBE NEWSWIRE) — MaxCyte, Inc.<\/a>, (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced they are entering into a strategic platform license (SPL) with TG Therapeutics<\/a>, a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.<\/p>\n

Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte\u2019s Flow Electroporation\u00ae<\/sup> technology and ExPERT\u2122 platform. In return, MaxCyte is entitled to receive annual licensing fees and program-related revenue.<\/p>\n

TG Therapeutics entered into an agreement with Precision BioSciences, Inc. and acquired a worldwide license to Precision\u2019s Azercabtagene Zapreleucel (azer-cel), an investigational allogeneic or \u201coff the shelf\u201d CD19 CAR T cell therapy program for autoimmune diseases and all other non-oncology indications.\u00a0TG received clearance by the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application for azer-cel in progressive forms of multiple sclerosis (MS) and is targeting commencement of a Phase 1 trial in 2025.<\/p>\n

\u201cBy leveraging our commercially validated cell-engineering platform and optimized T cell manufacturing workflow, TG Therapeutics is advancing toward their Phase 1 clinical trial for the application of azer-cel in progressive forms of MS,\u201d\u00a0said Maher Masoud, President and CEO of MaxCyte<\/strong>. \u201cOur technology has been integral to the manufacturing of allogeneic T cell immunotherapies and was efficiently transferred from Precision BioSciences when TG Therapeutics obtained global rights for azer-cel<\/a> for autoimmune diseases in January 2024.\u00a0With our new partnership, we will continue to support the development of azer-cel to expand the application to autoimmune diseases.\u201d<\/p>\n

MaxCyte\u2019s ExPERT\u2122 instrument portfolio is the next generation of leading, clinically and commercially validated electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency and cell viability, seamless scalability and enhanced functionality, the ExPERT\u2122 platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics.<\/p>\n

\n About MaxCyte<\/strong>
\n
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients\u2019 lives. We have spent more than 25 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today\u2019s processes to innovate tomorrow\u2019s solutions. Our ExPERT\u2122 platform, which is based on our Flow Electroporation\u00ae<\/em><\/sup>\u00a0technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx\u2122, STx\u2122, GTx\u2122 and VLx \u2122; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at\u00a0maxcyte.com<\/a>\u00a0and follow us on\u00a0X<\/a>\u00a0and\u00a0LinkedIn<\/a>.<\/p>\n

\n About TG Therapeutics<\/strong>
\n
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI\u00ae<\/sup> (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit\u00a0tgtherapeutics.com<\/a>,<\/u>\u00a0and follow us on X<\/a> (formerly Twitter) and on\u00a0LinkedIn<\/a>.<\/p>\n

\n MaxCyte Contacts:<\/strong>\n <\/p>\n

\n
\n US IR Adviser<\/em>
\n <\/strong>
\n
\n
\n Gilmartin Group<\/em>
\n <\/strong>
\n
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com<\/a><\/p>\n

\n
\n US Media Relations<\/em>
\n <\/strong>
\n
\n
\n Spectrum Science<\/em>
\n <\/strong>
\n
Jordan Vines
jvines@spectrumscience.com<\/a>
+1 540-629-3137<\/p>\n

\n
\n Nominated Adviser and Joint Corporate Broker<\/em>
\n <\/strong>
\n
Panmure Liberum
Emma Earl \/ Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500<\/p>\n

\n
\n UK IR Adviser<\/em>
\n <\/strong>
\n
\n
\n ICR Healthcare<\/em>
\n <\/strong>
\n
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@icrhealthcare.com<\/a><\/p>\n

\n TG Therapeutics Contact:<\/strong>\n <\/p>\n

\n
\n Investor Relations<\/em>
\n <\/strong>
\n
\n
\n Email:\u00a0<\/em>
\n <\/strong>
\n
\n
\n ir@tgtxinc.com<\/em>
\n <\/strong>
\n <\/a>
\n
\n
\n Telephone: 1.877.575.TGTX (8489), Option 4<\/em>
\n <\/strong>\n <\/p>\n

\n
\n Media Relations<\/em>
\n <\/strong>
\n
Email:\u00a0media@tgtxinc.com<\/a>
Telephone: +1 877-575-TGTX (8489), Option 6<\/p>\n

\n Forward-Looking Statements <\/strong>
\n
This press release contains \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.<\/p>\n

Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (\u201cSEC\u201d) on March 12, 2024, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 6, 2024. These documents are available through the Investor Menu, Financials section, under \u201cSEC Filings\u201d on the Investors page of our website at\u00a0http:\/\/investors.maxcyte.com<\/a>. Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of such press release, and you should not rely on forward-looking statements as predictions of future events. We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

TG Therapeutics to use MaxCyte\u2019s Flow Electroporation\u00ae technology and ExPERT\u2122 platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for the treatment of autoimmune diseases ROCKVILLE, Md., Feb. 12, 2025 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced they are entering into a strategic platform license (SPL) with TG Therapeutics, a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte\u2019s Flow … <\/p>\n

Continue reading “MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-811861","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TG Therapeutics to use MaxCyte\u2019s Flow Electroporation\u00ae technology and ExPERT\u2122 platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for the treatment of autoimmune diseases ROCKVILLE, Md., Feb. 12, 2025 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced they are entering into a strategic platform license (SPL) with TG Therapeutics, a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte\u2019s Flow … Continue reading "MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-12T07:03:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Njg5MiM2NzQ2NjQ0IzIyMDUxNzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs\",\"datePublished\":\"2025-02-12T07:03:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\\\/\"},\"wordCount\":1032,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1Njg5MiM2NzQ2NjQ0IzIyMDUxNzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\\\/\",\"name\":\"MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1Njg5MiM2NzQ2NjQ0IzIyMDUxNzg=\",\"datePublished\":\"2025-02-12T07:03:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1Njg5MiM2NzQ2NjQ0IzIyMDUxNzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1Njg5MiM2NzQ2NjQ0IzIyMDUxNzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\/","og_locale":"en_US","og_type":"article","og_title":"MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs - Market Newsdesk","og_description":"TG Therapeutics to use MaxCyte\u2019s Flow Electroporation\u00ae technology and ExPERT\u2122 platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for the treatment of autoimmune diseases ROCKVILLE, Md., Feb. 12, 2025 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced they are entering into a strategic platform license (SPL) with TG Therapeutics, a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte\u2019s Flow … Continue reading \"MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-12T07:03:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Njg5MiM2NzQ2NjQ0IzIyMDUxNzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs","datePublished":"2025-02-12T07:03:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\/"},"wordCount":1032,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Njg5MiM2NzQ2NjQ0IzIyMDUxNzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\/","name":"MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Njg5MiM2NzQ2NjQ0IzIyMDUxNzg=","datePublished":"2025-02-12T07:03:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Njg5MiM2NzQ2NjQ0IzIyMDUxNzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1Njg5MiM2NzQ2NjQ0IzIyMDUxNzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-tg-therapeutics-to-advance-its-autoimmune-cell-therapeutics-programs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/811861","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=811861"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/811861\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=811861"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=811861"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=811861"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}